Skip navigation
Pay Bill Portals
Covered by Medicare for patients with stage II-IV breast cancer

Signatera™ for Breast Cancer

Personalized, tumor-informed ctDNA molecular residual disease (MRD) testing for breast cancer to inform critical decisions for care.

Monitor Your Breast Cancer

The Signatera™ Residual Disease Test is a custom-built blood test for people who have been diagnosed with breast cancer or other solid tumors. Signatera™ can detect molecular residual disease (MRD) in the form of circulating tumor DNA—small fragments of DNA released by cancer cells.

How it works

The first time your doctor orders Signatera™, a one time tissue sample and a blood sample are needed to build your unique test. Natera will work with your cancer care team to access your tumor tissue from a prior procedure or surgery.

After your test is built, you will need to get your blood drawn each time your doctor orders Signatera™.

Repeated Signatera™ testing can show changes in your ctDNA levels, helping your doctor understand if your cancer is shrinking, growing, or coming back.

  • Inform Your Treatment Plan

    If you or a loved one have been diagnosed with breast cancer, you likely have many questions. When used alongside other tests, Signatera™ can help guide you and your doctor in the next steps in your care confidently and make more informed decisions.

  • Is there cancer left?
    After Treatment
    • Signatera™ testing after surgery and/or initial treatment can help your doctor learn if residual traces of cancer remain in your body. This information can help you and your doctor understand your risk of recurrence, decide on what treatment to recommend, and plan your monitoring strategy.1-4
    • Signatera™ is covered by Medicare for stage IIb and higher breast cancer patients
  • Is my cancer likely to come back?
  • Is my treatment working?

Providing Answers Throughout the Patient Journey

Danielle’s Story

When Danielle’s breast cancer molecular recurrence was detected by Signatera™ testing, she and her doctor had incentive to act quickly.

“Information and knowledge is power – that’s how you beat cancer.”

Danielle’s story underscores the importance of self-advocacy and how the right tools make all the difference.

Angela’s Story

Like many survivors, Angela has faced many questions throughout her journey with high risk breast cancer – what’s the next step in my treatment? Is the cancer ever going to come back? What’s causing this symptom?

Listen to the story of how she asked her doctor about Signatera™ to help monitor for recurrence and treatment response, giving her the peace of mind to move on with her life.

Monitor Your Breast Cancer

The Signatera™ Residual Disease Test is a custom-built blood test for people who have been diagnosed with breast cancer or other solid tumors. Signatera™ can detect molecular residual disease (MRD) in the form of circulating tumor DNA—small fragments of DNA released by cancer cells.

How it works

The first time your doctor orders Signatera™, a one time tissue sample and a blood sample are needed to build your unique test. Natera will work with your cancer care team to access your tumor tissue from a prior procedure or surgery.

After your test is built, you will need to get your blood drawn each time your doctor orders Signatera™.

Repeated Signatera™ testing can show changes in your ctDNA levels, helping your doctor understand if your cancer is shrinking, growing, or coming back.

Learn More About Signatera™

Breast Cancer Patient Brochure

Want to learn more about ctDNA monitoring for people living with breast cancer?

Download the Signatera™ Brochure

Breast Cancer Patient Discussion Guide

Interested in learning whether Signatera™ is right for you? Follow this discussion guide to speak with your doctor

Download the Patient Discussion Guide

Interview with Signatera™ patient Chloe Crampton

Circulating tumor DNA tests for peace of mind: an interview with Signatera™ patient Chloe Crampton

Read Here
Alt text

Good Morning America

Mariel Leibowitz and her doctor share how Signatera™ helped them keep an eye out for triple negative breast cancer recurrence.

Watch the Segment
Alt text

NPR

Bonnie shares how Signatera™ testing during and after bladder cancer treatment helped her “feel confident in enjoying life.”

Learn About Bonnie's Story
Alt text

Into Tomorrow with Dave Graveline

Solomon Moshkevich of Natera discusses the potential of personalized ctDNA testing to change breast cancer care.

Listen to the Interview

Access Personalized Testing

Medicare Coverage

  • Signatera™ is covered by Medicare for patients with stage II-IV breast cancer in the neoadjuvant setting, regardless of subtype and stage IIb and higher breast cancer in the adjuvant and recurrence monitoring settings.
  • We welcome all insurance plans. Please refer to our list of in-network plans that we participate with, or call your insurance provider.
  • We offer financial assistance programs for those who qualify.
Learn More

More Information

  • Find answers to your questions about eligibility, results, ordering, and more
  • Don’t see your question? Contact us here.
  • Learn more about Signatera™ testing in our Patient Resource Library
FAQ

Check Out Additional Resources From Some of Our Advocacy Partners

Organization Logo

Learn Look Locate

Learn Look Locate is a global community dedicated to educating, inspiring, and connecting people with breast cancer through survivor stories and other resources.

learnlooklocate.com
Organization Logo

Sharsheret

Sharsheret provides support, education, and information to improve the lives of Jewish women and families who may have an increased genetic risk for breast and ovarian cancer.

sharsheret.org
Organization Logo

Susan G. Komen

The mission of Susan G. Komen is to save lives by meeting the most critical needs in our communities and investing in breakthrough research to prevent and cure breast cancer.

komen.org/
Organization Logo

The Breasties

The Breasties is the first all-inclusive nonprofit organization that creates community for survivors, previvors, stage 4 thrivers, and caregivers impacted by breast and gynecologic cancers.

thebreasties.org
Organization Logo

Force

FORCE improves the lives of the millions of individuals and families facing hereditary breast, ovarian, pancreatic, prostate, colorectal and endometrial cancers.

facingourrisk.org

Is Signatera™ right for you?

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

1Coombes RC, et al. Clin Cancer Res. 2019 Jul 15;25(14):4255-4263.

2Magbanua MJM, et al. Ann Oncol. 2021; 32(2):229-239.

3Magbanua MJM, et al. Comparison of the predictive and prognostic significance of circulating tumor DNA in patients with high risk HER2-negative breast cancer receiving neoadjuvant chemotherapy. AACR; April 8-13, 2022.

4Cutts R, et al. Detection of ctDNA following surgery predicts relapse in breast cancer patients receiving primary surgery. SABCS; December 7-11, 2021.

5Shaw JA, et al. Serial postoperative ctDNA monitoring for early detection of breast cancer recurrence. ASCO; June 3-7, 2022.

6Bratman SV, et al. Nature Cancer. 2020;1(9):873-881.

icon-angle icon-bars icon-times